Skip to main content

Drug Interaction Report

3 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

pivmecillinam cefditoren

Applies to: pivmecillinam, Spectracef (cefditoren)

GENERALLY AVOID: Concomitant use of pivmecillinam with valproate or other pivalate-generating medications (e.g., cefditoren pivoxil, adefovir dipivoxil) may increase the risk of carnitine depletion. The proposed mechanism is additive reduction of carnitine levels that occur when pivmecillinam is coadministered with other pivalate-generating medications. Pivmecillinam has been reported to reduce serum carnitine concentrations due to the reaction of pivalic acid with carnitine to form pivaloyl carnitine, which is excreted in the urine. Reduced carnitine levels may increase the risk of valproate-induced hyperammonemic encephalopathy. A case report describes hyperammonemic encephalopathy that developed in a 72-year old woman on valproate monotherapy (1500 mg/day) for partial epilepsy who was given pivmecillinam (200 mg three times daily) for a urinary tract infection. Her condition resolved after discontinuation of pivmecillinam and valproate and replacement with IV cefuroxime and gabapentin. Drug interaction studies with other pivalate-generating medications are unavailable. However, carnitine depletion can be expected. Additionally, a similar interaction with pivalate-generating medications may occur following the use of pivampicillin.

MANAGEMENT: The manufacturer of pivmecillinam advises that concomitant use with valproate or other pivalate-generating medications should be avoided. If concomitant use is required, patients should be monitored for signs and symptoms of carnitine depletion (such as muscle aches, fatigue, confusion, and hypoglycemia) and hyperammonemic encephalopathy (such as acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting). Discontinuation of both medicines and initiation of appropriate therapeutic management should be considered if these signs and symptoms develop.

References (6)
  1. Home E, Greter J, Jacobsen CE, et al. (1989) "Carnitine deficiency induced by pivampicillin and pivmecillinam therapy." Lancet, 2(8661), p. 469-73
  2. Lokrantz CM, Eriksson B, Rosen I, Asztely F (2004) "Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam." Acta Neurol Scand, 109, p. 297-301
  3. (2024) "Product Information. Pivya (pivmecillinam)." UTILITY Therapeutics Ltd
  4. (2024) "Product Information. Pivmecillinam (pivmecillinam)." Milpharm Ltd
  5. Brass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppel CL (2003) "Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil" Clin Pharmacol Ther, 73, p. 338-47
  6. Tichy T, andrei g, Dracinsky M, Holy A, Balzarini J, snoeck r, Krecmerova M (2011) "New prodrugs of adefovir and cidofovir" Bioorg Med Chem, 19, p. 3527-39

Drug and food interactions

Moderate

cefditoren food

Applies to: Spectracef (cefditoren)

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of cefditoren pivoxil. According to the manufacturer, administration of cefditoren pivoxil following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 50% and 70%, respectively, compared to administration in the fasting state. The absolute bioavailability of cefditoren pivoxil is approximately 14% under fasting conditions and 16% when given with a low-fat meal.

MANAGEMENT: To ensure maximal oral absorption, cefditoren pivoxil should be administered with or immediately after a meal.

References (1)
  1. (2001) "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Beta-lactam antibiotics

Therapeutic duplication

The recommended maximum number of medicines in the 'beta-lactam antibiotics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'beta-lactam antibiotics' category:

  • pivmecillinam
  • Spectracef (cefditoren)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.